Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Behind every facility expansion, technology investment, and quality milestone in the CDMO sector is a leadership team making deliberate choices about where to focus, how to grow, and when to take calculated risks.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
A video roundup of the week’s top industry news stories.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
Contract Pharma Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Cavanaugh’s tenure as EVP and Worldwide Chairman, Innovative Medicine begins in September.
August 4, 2026
By: Patrick Lavery
Why This Matters: See our coverage of other industry executive team appointments and promotions here.
Johnson & Johnson announced the impending retirement of Executive Vice President (EVP) Jennifer Taubert, with Tom Cavanaugh to succeed her. Cavanaugh’s full title, as was Taubert’s, will be EVP, Worldwide Chairman, Innovative Medicine. Following a transition this month, Cavanaugh joins the Johnson & Johnson Executive Committee Sept. 1, 2026.
Tom Cavanaugh joined Johnson & Johnson in 2017 and currently serves as Company Group Chairman, North America, Innovative Medicine. Previously, he held senior leadership positions in oncology, immunology, and global commercial strategy, enhancing nearly three decades of biopharmaceutical experience. Before coming to Johnson & Johnson, Cavanaugh spent nearly 15 years at Celgene, serving the United States and Spain.
Johnson & Johnson Chairman and CEO Joaquin Duato said Cavanaugh will help to continue advancing a pipeline of “transformative” medicines. Duato cited Cavanaugh’s “deep understanding of our business, proven track record of growth, and focus on developing people.”
Meanwhile, Taubert concludes a tenure of more than two decades at Johnson & Johnson. In that time, the company’s annual revenue for its Innovative Medicine business grew past $60 billion. Also during this period, she was recognized by Fortune’s Most Powerful Women list for 10 consecutive years.
“Jennifer has made an extraordinary impact on patients, our business, and generations of leaders across our company,” Duato said. “Her vision, leadership, unwavering commitment to healthcare innovation, and passion for talent development helped define an era of growth.”
As Cavanaugh takes over, Johnson & Johnson says it is looking to his record of “authentic leadership.” This, the company says, will further unite its teams around a shared purpose and demonstrate a commitment to developing talent.
Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
